ARTICLE | Clinical News

KP415: Preliminary Ph I KP415.101 data

December 30, 2016 1:21 AM UTC

Preliminary data from the open-label, crossover Phase I KP415.101 trial in 24 healthy volunteers showed that a single dose of 32 mg oral KP415 under fasted conditions was generally well tolerated with...

BCIQ Company Profiles

Zevra Therapeutics Inc.